— Know what they know.
Not Investment Advice
Also trades as: 2269.HK (HKSE) · $vol 208M · WXXWY (OTC) · $vol 1M

WXIBF OTC

WuXi Biologics (Cayman) Inc.
1W: -14.9% 1M: -20.1% 3M: +17.6% YTD: +28.2% 1Y: +20.2% 3Y: +6.1% 5Y: -70.5%
$5.41
+0.03 (+0.56%)
 
Weekly Expected Move ±16.6%
$4 $5 $6 $7 $8
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 37 · $22.3B mcap · 3.75B float · 0.0001% daily turnover · Short 35% of daily vol
Credit Risk of going bust: lower than 79% of companies Debt: 1.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down 99.9%), WuXi Biologics (Cayman) Inc. would be worth roughly what it owes.
Total debt $409.5M against a stock market value of $22.27B.
Distance to default 9.40 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $67.7M (short-term plus half of long-term), stock volatility 60.4%; Altman Z'' 7.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

No ESG data available for WXIBF

ESG scores are derived from SEC filings (10-K, 10-Q) and may not be available for all companies.

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms